CYP3A4 drug metabolism considerations in pediatric pharmacotherapy
Open Access
- 5 December 2024
- journal article
- review article
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 33 (12) , 2221-2235
Abstract
Cytochrome P450 3A4 (CYP3A4) is a crucial enzyme involved in the Phase I metabolism of numerous medications used in clinical practice. Its potential significance in pediatric pharmacotherapy is underscored by the unique metabolic profile of children, which differs markedly from adults, especially in neonates, infants, and young children due to developmental changes in enzyme activity. This review explores the critical role of CYP3A4 in the metabolism of drugs used in the pediatric population, with a particular focus on combination drug therapies. Given the high potential for drug-drug interactions in combination therapies, understanding the modulation of CYP3A4 activity is essential for optimizing therapeutic outcomes and minimizing adverse effects. This paper further examines the structural similarities between these medications and bergamottin, a known CYP3A4 inhibitor found in citric fruits such as grapefruit. Variability in CYP3A4 activity, influenced by genetic polymorphisms, developmental stage, and external factors, necessitates careful consideration in the prescribing and management of drugs in children. This review corroborates the need for personalized medicine approaches and enhanced pharmacovigilance to ensure the safe and effective use of CYP3A4-metabolized drugs in the pediatric population. Graphical AbstractKeywords
Funding Information
- South Carolina SmartState® Program in Medication Safety and Efficacy
This publication has 45 references indexed in Scilit:
- Combining data on the bioavailability of midazolam and physiologically‐based pharmacokinetic modeling to investigate intestinal CYP3A4 ontogenyCPT: Pharmacometrics & Systems Pharmacology, 2024
- Personalized Dosing of Medicines for Children: A Primer on Pediatric Pharmacometrics for CliniciansPediatric Drugs, 2024
- Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy ParticipantsClinical Pharmacology in Drug Development, 2024
- A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/RitonavirClinical Pharmacokinetics, 2024
- The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizationsMedicinal Chemistry Research, 2022
- Impact of Inflammation on Cytochromes P450 Activity in Pediatrics: A Systematic ReviewClinical Pharmacokinetics, 2021
- Impact of Hepatic CYP3A4 Ontogeny Functions on Drug–Drug Interaction Risk in Pediatric Physiologically‐Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case StudyClinical Pharmacology & Therapeutics, 2020
- Developmental Changes in the Expression and Function of Cytochrome P450 3A Isoforms: Evidence from In Vitro and In Vivo InvestigationsClinical Pharmacokinetics, 2013
- Bergamottin contribution to the grapefruit juice?felodipine interaction and disposition in humansClinical Pharmacology & Therapeutics, 2004
- Cytochromes P-450Comparative Biochemistry and Physiology Part C: Comparative Pharmacology, 1988